|
‘A highly focused meeting on current problems and issues with a good selection of speakers’ Cédric Merlot, Cheminformatics Scientist, Scientific Computing, Merck Serono Delegate at SMi’s In Silico ADMET conference 2007
How a drug interacts with the biology of a living organism can be extremely complex. Predicting the likely behaviour of a drug early in the development process is crucial if the resources put into developing a drug candidate are to be justified. Under the current research and development budgets, effectively and accurately predicting a drug’s behaviour has never been more vital. SMi’s 3rd annual ADMET conference will update you with the very latest modelling systems, technologies and knowledge, helping you provide an increasingly accurate picture of ADME properties, drug-drug interactions and toxicity throughout your studies. This Conference gathers experts in the prediction of human metabolic fate, pharmacokinetics and toxicity of drug candidates, covering in silico, in vitro and in vivo approaches. It is an important event for everyone in the field of drug discovery.
Critical challenges that will be addressed: - UNDERSTAND current in vivo and in vitro strategies
- EVALUATE the most viable methods, models and systems currently in use
- DISCUSS the integration and development of different systems for predicting both ADME and toxicity
- ASSESS the potential for more advanced high-throughput and in silico approaches
- IDENTIFY how resulting data can be handled and analysed
Exclusive presentations from industry experts including:
- Marcel de Groot, Senior Principal Scientist, Chemistry, Pfizer
- Vijay Gombar, Research Advisor, Drug Disposition – Computational ADME, Eli Lilly
- Andrew Baxter, Principal Scientist, Medicinal Chemistry, AstraZeneca
- Niels Kruize, Sales Director, KBioscience
- Prof. John Dearden, Emeritus Professor, School of Pharmacy and Chemistry, Liverpool John Moores University
- Paul Czodrowski, Scientist, Boehringer Ingelheim GmbH
- Janice Yau Yi Lau, Group Leader, Advanced Technology, Global Pharmaceutical Discovery, Abbott Laboratories
- Douglas Ferguson, Team Leader, Discovery DMPK, AstraZeneca
- Cédric Merlot, Cheminformatics Scientist, Genkyotex
- Willem Schoonen, Group Leader, In Vitro Toxicology and Toxigenomics, DMPK & Safety, Schering-Plough Research Institute
- Nigel Greene, Associate Research Fellow, Computational Toxicology, Pfizer
- Andrea Rübe, Formulation Research Scientist, CMC Development, Exploratory Development, Merck Serono
- Brian Mattioni, Senior Research Scientist, Drug Disposition, Eli Lilly
- Mette Guldbrandt, Section Head, ADME and Assay Technology, Novo Nordisk
- Karrar Khan, Former Director, Pharmaceutical Development, OSI Pharmaceuticals
- György Keseru, Manager, Discovery Chemistry, Gedeon Richter Ltd
- Alex Watson, Chief Executive Officer, Abcellute
- Andreas Bernkop-Schnurch, Chair of Pharmaceutical Technology, University of Innsbruck
- Pransas Japertas, Director of Development, Pharma Algorithms
- Katya Tsaioun, President, Apredica
- Yojiro Sakiyama, Principal Scientist, In Silico Modelling Specialist, Pharmacokinetics Dynamics Metabolism, Pfizer
- Sheila Annie Peters, Associate Principal Scientist, Discovery DMPK & Bioanalytical Chemistry, AstraZeneca R&D
- Hinnerk Boriss, Chief Executive Officer, Sovicell GmbH
- Robert Fraczkiewicz, Team Leader, ADMET Cheminformatics, Life Sciences, Simulations Plus Inc
- Tai Huang, Director, R&D, Linden Bioscience
You will benefit from attending this event if you are:
A Vice President, Director or Manager from within the pharmaceutical or biotech industry with responsibilities in the following areas: - Drug Discovery
- Preclinical Development
- ADME
- DMPK
- Pharmacokinetics
| - Toxicology / metabolism
- Computational Chemistry
- Molecular Modeling
- Cheminformatics
- Drug Design
| - Structural Biologists
- Biomolecular Screening
- Medicinal Chemistry
- Lead Optimisation
- Physical Chemistry
|
Last years’ delegates were from:
- GlaxoSmithKline
- Eli Lilly & Co.
- Pfizer Inc.
- Merck Serono International
- AstraZeneca
| - Bayer HealthCare AG
- Abbott Laboratories
- Jerini AG
- Merck Genome Research Institute
- Organon NV
| - Boehringer Ingelheim GmbH & Co.
- Amgen
- Roche Products Ltd.
- Epix Pharmaceuticals Ltd.
|
For Speaking opportunities please contact Mamta Patel at mpatel@smi-online.co.uk
|
Events Home Page
